APA (7th ed.) Citation

SH, K., HJ, Y., SK, H., SY, Y., TH, K., YS, L., . . . SK, B. (2026). Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. Journal of gastroenterology and hepatology, 41(5), 1583. https://doi.org/10.1111/jgh.70326

Chicago Style (17th ed.) Citation

SH, Kang, et al. "Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB." Journal of Gastroenterology and Hepatology 41, no. 5 (2026): 1583. https://doi.org/10.1111/jgh.70326.

MLA (9th ed.) Citation

SH, Kang, et al. "Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB." Journal of Gastroenterology and Hepatology, vol. 41, no. 5, 2026, p. 1583, https://doi.org/10.1111/jgh.70326.